P25. Access to diagnostics: a bottleneck for immunotherapeutics development - case example of MAGE-A3 cancer immunotherapeutic

por Lykopoulos, K, Collins, P, Hall, M, Ehness, R, Barth, J, Louahed, J
Publicado 2014

Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study

por Gutzmer, R, Rivoltini, L, Levchenko, E, Testori, A, Utikal, J, Ascierto, P A, Demidov, L, Grob, J J, Ridolfi, R, Schadendorf, D, Queirolo, P, Santoro, A, Loquai, C, Dreno, B, Hauschild, A, Schultz, E, Lesimple, T P, Vanhoutte, N, Salaun, B, Gillet, M, Jarnjak, S, De Sousa Alves, P M, Louahed, J, Brichard, V G, Lehmann, F F
Publicado 2016